Zura Bio (NASDAQ:ZURA) Stock Price Target Cut by Oppenheimer

Key Points

• Oppenheimer lowered its price target on Zura Bio to $5 but maintained an “outperform” rating; the target implies 247.71% upside from the prior close.
• Zura Bio’s TibuSHIELD Phase 2 study missed its primary endpoint, prompting the company to end development of tibulizumab for hidradenitis suppurativa.
• Investor law firms have announced investigations into whether investors were adequately informed about the program before the trial result; these are investigations, not findings of wrongdoing.

Zura Bio (NASDAQ:ZURA - Get Free Report) had its price target lowered by research analysts at Oppenheimer to $5.00 in a report released on Tuesday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Oppenheimer's price target would indicate a potential upside of 247.71% from the stock's previous close.

A number of other equities research analysts have also commented on the stock. Wall Street Zen raised shares of Zura Bio from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 1st. Wedbush increased their target price on Zura Bio from $15.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Weiss Ratings upgraded Zura Bio from a "sell (d-)" rating to a "sell (d)" rating in a report on Wednesday, October 28th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Zura Bio in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Zura Bio presently has an average rating of "Moderate Buy" and a consensus target price of $14.50.

Zura Bio Trading Up 16.0%

Zura Bio stock traded up $0.20 during midday trading on Tuesday, reaching $1.44. The company's stock had a trading volume of 10,362,523 shares, compared to its average volume of 1,765,224. The business has a 50-day moving average price of $4.36 and a 200-day moving average price of $5.18. The stock has a market cap of $137.80 million, a PE ratio of -1.26 and a beta of 0.03. Zura Bio has a 52 week low of $0.93 and a 52 week high of $7.44.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). As a group, research analysts predict that Zura Bio will post -0.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ZURA. Montanova Capital LLC boosted its position in Zura Bio by 4.1% during the 2nd quarter. Montanova Capital LLC now owns 9,443,001 shares of the company's stock valued at $55,714,000 after buying an additional 376,000 shares during the period. Siren L.L.C. increased its position in shares of Zura Bio by 187.3% during the first quarter. Siren L.L.C. now owns 3,734,866 shares of the company's stock valued at $22,222,000 after acquiring an additional 2,434,866 shares in the last quarter. Commodore Capital LP bought a new position in Zura Bio during the 1st quarter valued at about $19,338,000. Affinity Asset Advisors LLC increased its position in shares of Zura Bio by 41.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,564,303 shares of the company's stock valued at $15,258,000 after purchasing an additional 750,632 shares during the last quarter. Finally, EcoR1 Capital LLC bought a new position in shares of Zura Bio in the first quarter worth about $7,019,000. 61.14% of the stock is owned by institutional investors.

Zura Bio News Roundup

Here are the key news stories impacting Zura Bio this week:

• Neutral Sentiment: Options trading was unusually active, with 3,037 call contracts traded—57% above typical volume. This indicates increased activity but does not, by itself, establish whether traders expect shares to rise or fall.
• Negative Sentiment: The TibuSHIELD Phase 2 study missed its primary endpoint, and Zura Bio ended tibulizumab development for hidradenitis suppurativa. The result removes a potential program from the company’s pipeline and is the key negative catalyst in the recent coverage. Zura Bio clinical update and investigation notice Fierce Biotech report
• Negative Sentiment: Investor law firms announced investigations following the trial result. One notice points to Zura Bio’s October 27 SEC filing, which described tibulizumab as advancing in Phase 2, and questions whether investors were adequately informed before the study failed. These are investigations, not findings of wrongdoing, but may add uncertainty and reputational risk. Levi & Korsinsky investigation notice SBS Law investigation notice

About Zura Bio

Zura Bio, Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company's research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage.

Zura Bio's lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.